01Approach to the Critical Patient/attcp56

Immediate recognition and stabilization

›Life-threatening presentation triggers

›SpO2 plateau around 85% unresponsive to supplemental oxygen

›Hallmark saturation gap distinguishing methemoglobinemia from hypoxic etiologies

›PaO2 on ABG typically normal despite low pulse oximetry reading

›Chocolate brown blood appearance

›Does not turn red on exposure to oxygen or air

›Bedside diagnostic clue prior to co-oximetry confirmation

›Altered mental status

›Lethargy and stupor at MetHb >50%

›Seizures possible at severe levels

›Cardiovascular collapse

›Hypotension and shock at MetHb >55-70%

›Cardiac arrhythmias as late complication

›Immediate resuscitation actions

›High-flow oxygen via non-rebreather mask

›Maintains dissolved oxygen despite inability to correct MetHb fraction

›Supportive measure until antidote takes effect

›Remove offending agent immediately

›Discontinue causative medication or antidote

›Decontamination if topical or dermal exposure

›IV access and monitoring

›Continuous cardiac monitoring

›Pulse oximetry with awareness of SpO2 unreliability

›Emergent methylene blue if MetHb >25% or symptomatic at lower levels

›1 mg/kg IV over 5-30 minutes

›Repeat at 1 hour if inadequate response

02History/hx79

Exposure history

›Causative agent identification

›Topical anesthetics

›Benzocaine (highest risk among local anesthetics)

›Prilocaine

›Lidocaine (lower risk)

›Systemic medications

›Dapsone (may cause delayed and rebound methemoglobinemia)

›Phenazopyridine (Pyridium)

›Primaquine and chloroquine

›Sulfonamides

›Metoclopramide

›Nitroglycerin and nitrate medications

›Recreational and industrial exposures

›Amyl and isobutyl nitrite poppers

›Aniline dyes and industrial chemicals

›Propanil herbicide

›Cocaine adulterants

›Environmental sources

›Nitrate-contaminated well water

›Improperly stored vegetable broth (spinach, beets, carrots) in infants

Symptom timeline

›Onset and progression

›Timing relative to exposure

›Minutes to hours for direct oxidizers (benzocaine, nitrites)

›Hours to days for metabolically activated agents (dapsone)

›Symptom progression pattern

›Dyspnea and fatigue as early symptoms

›Headache, lightheadedness, nausea

›Anxiety and agitation at MetHb 20-50%

›Confusion and syncope at higher levels

›Procedure context

›Recent endoscopy, bronchoscopy, or transesophageal echocardiogram

›Topical anesthetic application

Review of systems

›Cardiopulmonary symptoms

›Dyspnea

›Often out of proportion to auscultatory findings

›Exertional limitation

›Chest pain or tightness

›Palpitations or tachycardia

›Neurological symptoms

›Headache and dizziness

›Confusion and altered awareness

›Syncope

›Seizure history

›Skin symptoms

›Cyanosis onset and distribution

›Generalized versus peripheral

›Gray or slate-blue discoloration description

Past medical and medication history

›Relevant medical history

›Prior methemoglobinemia episodes

›Common with recurrent dapsone use

›Congenital predisposition possible

›G6PD deficiency

›Critical for methylene blue planning

›Affects approximately 2% of US population

›Cardiopulmonary comorbidities

›Anemia, COPD, asthma, heart disease

›Lower MetHb threshold for symptomatic presentation

›Congenital hemoglobinopathies

›Renal impairment for methylene blue dose adjustment

›Current medications review

›Serotonergic medications

›SSRIs, SNRIs, MAOIs, bupropion, linezolid, tramadol

›Methylene blue is a potent MAOI — serotonin syndrome risk

›Oxidizing medications

›Psychiatric history and intentional ingestion assessment

Family history and collateral

›Congenital methemoglobinemia clues

›Lifelong cyanosis in family members

›Autosomal recessive cytochrome b5 reductase deficiency (CYB5R3 mutations)

›Autosomal dominant hemoglobin M disease

›Type I congenital (CYB5R3 erythrocyte deficiency)

›Cyanosis only, benign course

›Type II congenital (CYB5R3 generalized deficiency)

›Cyanosis plus severe encephalopathy, microcephaly, dystonia

›Poor neurological prognosis

›Consanguinity increasing recessive form risk

›Collateral history

›Witnesses to exposure or ingestion

›Empty pill bottles or chemicals at scene

›Suicidal intent assessment

03Physical Exam/exam57

Vital signs and hemodynamic assessment

›Vital sign pattern

›Pulse oximetry

›Characteristic plateau near 85% regardless of true MetHb level

›Unreliable — does not accurately reflect oxygenation status

›Tachycardia

›Compensatory response to impaired oxygen delivery

›Severity marker when combined with cyanosis

›Tachypnea

›Severity marker

›May be disproportionately mild relative to cyanosis

›Hypotension

›Late finding in severe methemoglobinemia

›MetHb >55% threshold for cardiovascular compromise

Skin and appearance

›Cyanosis characteristics

›Distribution and quality

›Generalized gray or slate-blue discoloration

›Disproportionate to degree of respiratory distress

›Peripheral versus central cyanosis distinction

›Central cyanosis involves lips and mucous membranes

›Distinguishes from peripheral causes

›Oxygen response

›Persistent cyanosis despite high-flow oxygen is key finding

›Blood appearance

›Chocolate brown color

›Remains brown when exposed to air unlike normal deoxygenated blood

›Remains brown when placed on white filter paper

04Differential Diagnosis/ddx43

Life-threatening mimics

›Immediate threats requiring differentiation

›Carbon monoxide poisoning

›ICD-10 T58.XX

›Co-oximetry shows elevated COHb, normal MetHb

›Cherry-red skin possible, SpO2 falsely normal on standard pulse ox

›Cyanide poisoning

›ICD-10 T65.0XX

›Lactic acidosis prominent, bitter almond odor

›May co-occur with smoke inhalation

›Pulmonary embolism

›ICD-10 I26.XX

›Hypoxemia improves with supplemental oxygen

›Pleuritic pain and risk factors present

›Severe pneumonia and ARDS

›ICD-10 J18.9, J80

›Hypoxemia typically improves with oxygen

›Abnormal auscultation and imaging findings

Dyshemoglobin disorders

›Related toxic hemoglobin states

›Sulfhemoglobinemia

›Irreversible hemoglobin oxidation

›Does not respond to methylene blue

›Co-oximeters may misidentify as MetHb

›Distinguishing clue: deeper greenish cyanosis, no antidote response

›Congenital methemoglobinemia

›ICD-10 D74.0

›Lifelong cyanosis from birth

05Laboratory Tests/lt52

Core diagnostic labs

›Co-oximetry — gold standard

›ABG with co-oximetry panel

›Directly measures MetHb fraction (normal <3%)

›Simultaneously measures OxHb, DeoxHb, COHb

›PaO2 typically normal as dissolved oxygen unaffected

›Calculated SaO2 on ABG will be falsely normal — use measured co-ox value

›Saturation gap interpretation

›SpO2 (pulse ox) minus SaO2 (co-oximetry) gap

›Gap >5% suggests dyshemoglobinemia

›Hematologic labs

›Complete blood count

›Baseline hemoglobin for oxygen carrying capacity

›Hemolytic anemia concern especially post-methylene blue in G6PD deficiency

›Reticulocyte count

›Hemolysis confirmation

›Regenerative response

›Peripheral blood smear

›Heinz bodies and bite cells in oxidative hemolysis

›Haptoglobin, LDH, indirect bilirubin

›Hemolysis markers

›Monitor if methylene blue given to potentially G6PD-deficient patient

Metabolic and organ function labs

›Renal function

›Creatinine and eGFR

›Methylene blue dose limitation in moderate to severe impairment

›eGFR 15-59: limit to single dose 1 mg/kg

›Electrolytes

06Diagnostic Tests/dt69

Scoring Systems

›Severity classification by MetHb level

›MetHb <10%

›Usually asymptomatic

›Possible mild cyanosis

›Observation and agent removal

›MetHb 10-20%

›Cyanosis, headache, anxiety

›Supplemental oxygen and monitoring

›MetHb 20-30%

›Dyspnea, fatigue, tachycardia

›Methylene blue strongly considered

›MetHb 30-50%

›Confusion, severe dyspnea

›Methylene blue mandatory

›MetHb >50%

›Seizures, coma, arrhythmias

›Emergency treatment with methylene blue plus supportive care

›MetHb >70%

›Usually fatal without immediate intervention

›Clinical severity integration

›Shock at presentation is sole independent prognostic factor for mortality

›Based on 10-year retrospective study

›MetHb level alone does not determine outcome

›Comorbidities lower symptomatic threshold

›Anemia, COPD, cardiac disease symptomatic at lower MetHb

MRI

›MRI role in methemoglobinemia

07Disposition/dispo44

Admission indications

›ICU or high-acuity level care

›MetHb >30% at presentation

›Antidote required

›Close monitoring for rebound and hemolysis

›Hemodynamic instability

›Hypotension or arrhythmia

›Vasopressor requirement

›Altered mental status or seizures

›Ongoing neurological monitoring

›Airway protection concern

›Dapsone as causative agent

›Prolonged and relapsing course expected

›Rebound methemoglobinemia 12-24 hours after initial treatment

›G6PD deficiency with hemolysis

›Transfusion planning may be needed

›General ward admission

›MetHb 15-30% with symptoms but hemodynamically stable

›Antidote administered in ED

›Monitoring for rebound

›Need for further investigation of causative agent

›Ongoing occupational or environmental exposure risk

Discharge criteria

›Safe discharge requirements

›MetHb <10% with complete symptom resolution

›Following observation period

›No evidence of hemolysis

›Stable vital signs

08Treatment/t92

Immediate antidote — methylene blue

›Methylene blue administration

›Indication

›MetHb >25-30% regardless of symptoms

›Symptomatic at any level with cardiopulmonary compromise

›Lower threshold in patients with anemia or cardiopulmonary disease

›Dosing protocol

›1 mg/kg IV over 5-30 minutes

›Slower infusion reduces adverse effects

›Maximum infusion rate consideration for hemodynamic monitoring

›Repeat dose at 1 hour if MetHb remains >30% or symptoms persist

›Second dose 1 mg/kg IV

›Maximum 2 doses as a standard course

›Renal impairment modification

›eGFR 15-59: limit to single dose 1 mg/kg

›eGFR <15: use with extreme caution, poison control guidance

›Response monitoring

›Repeat co-oximetry 30-60 minutes after dose

›Clinical improvement within 20-30 minutes expected

›Urine turns green or blue — expected adverse effect, not harmful

›Mechanism of action

›Methylene blue activates NADPH methemoglobin reductase

›Requires functional G6PD to generate NADPH

›Ineffective in G6PD deficiency

›Reduces MetHb back to functional hemoglobin

›Paradoxical worsening at high doses

›Doses >7 mg/kg can cause methemoglobinemia via direct oxidation

›Stay within recommended dose range

Methylene blue contraindications and cautions

›Absolute and relative contraindications

›G6PD deficiency

›Methylene blue ineffective and may cause severe hemolytic anemia

›Real-time G6PD result rarely available — empiric clinical decision

›Alternative antidotes must be considered

›Serotonin syndrome risk

›Methylene blue is a potent reversible MAO inhibitor

›Avoid concomitant use with SSRIs, SNRIs, MAOIs, opioids, dextromethorphan, bupropion, buspirone, clomipramine, mirtazapine, linezolid, tramadol

›If unavoidable, use lowest dose and monitor for CNS toxicity for at least 4 hours

›Serotonergic drugs should not be taken within 72 hours after last methylene blue dose

›Prior anaphylaxis to methylene blue class products

›Special precautions

›Pregnancy — methylene blue can cause intestinal atresia if given intra-amniotically

›IV administration for maternal methemoglobinemia is acceptable

›High-dose monitoring for paradoxical methemoglobinemia

Alternative antidotes

›When methylene blue fails or is contraindicated

›Ascorbic acid (vitamin C)

›1-2 g IV slowly as adjunct

›Weaker and slower mechanism than methylene blue

›G6PD-independent pathway — useful when G6PD deficiency suspected

›Not adequate as sole therapy in severe cases

›N-acetylcysteine

›Adjunct antioxidant therapy

›Replenishes glutathione for oxidative stress

›Standard NAC dosing protocols apply

›Exchange transfusion

›Severe refractory cases with cardiovascular compromise

›G6PD deficiency with life-threatening MetHb

›Replaces methemoglobin-laden red blood cells

›Hyperbaric oxygen

›Increases dissolved plasma oxygen to bypass MetHb impairment

›Specialist center availability limits utility

›Consider if methylene blue contraindicated and exchange transfusion unavailable

Supportive care

›Oxygen therapy

›100% oxygen via non-rebreather mask

›Maximizes dissolved plasma oxygen

›Supportive while awaiting antidote effect

›Intubation with FiO2 1.0 if airway compromise

›Hemodynamic support

›IV fluid resuscitation for hypotension

›Crystalloid 10-20 ml/kg bolus

›Vasopressors if fluid-unresponsive shock

›Norepinephrine 0.1-0.3 mcg/kg/min as first-line vasopressor

›Titrate to MAP >65 mmHg

›Seizure management

›Benzodiazepine first-line

›Lorazepam 0.1 mg/kg IV (max 4 mg per dose)

›Diazepam 0.15 mg/kg IV alternative

›Treat underlying methemoglobinemia as definitive seizure treatment

›Decontamination

›Dermal exposure

›Remove contaminated clothing

›Wash skin with soap and water

›Oral ingestion

›Activated charcoal 1 g/kg PO if ingestion within 1 hour and airway intact

›Gastric lavage for large ingestion when charcoal not adequate

Rebound methemoglobinemia management

›Dapsone-specific protocol

›Prolonged elimination half-life of dapsone (20-30 hours)

›Rebound MetHb elevation 12-24 hours after initial methylene blue

›Repeat co-oximetry at 4 and 12 hours minimum

›Cimetidine adjunct for dapsone cases

›400 mg PO three times daily

›Inhibits dapsone metabolic activation to hydroxylamine

›Reduces ongoing MetHb generation

›Extended observation or admission for all dapsone cases

09Special Populations/sp75

Pregnancy

›Physiologic considerations in pregnancy

›Increased blood volume and physiologic anemia

›Lower hemoglobin baseline reduces oxygen carrying reserve

›Fetal hemoglobin has higher affinity for oxygen but cannot bind when oxidized

›Fetal vulnerability

›Fetal HbF highly susceptible to oxidation

›Placental transfer of oxidizing agents

›Fetal oxygen delivery critically dependent on maternal MetHb level

›Maternal threshold for treatment lower

›Treat at MetHb >15-20% in pregnancy

›Fetal monitoring when MetHb significant

›Treatment modifications

›Methylene blue in pregnancy

›IV administration for maternal methemoglobinemia is acceptable

›Intra-amniotic injection associated with fetal intestinal atresia — avoid this route

›Benefit outweighs risk in severe maternal methemoglobinemia

›Ascorbic acid

›Generally safe in pregnancy as adjunct

›Exchange transfusion

›Last resort; involves obstetrics and hematology

›Causative agent avoidance in pregnancy

›Benzocaine-containing products avoided

›Dapsone use requires monitoring

›Nitrate-contaminated water avoidance counseling

Geriatric

›Age-related vulnerability

›Reduced cytochrome b5 reductase activity with aging

›Slower MetHb reduction capacity

›Symptomatic at lower MetHb levels

›Higher prevalence of comorbidities

›Coronary artery disease lowers ischemic threshold

›Anemia common in older adults

›COPD reduces baseline oxygen reserve

›Medication considerations

›Polypharmacy increases serotonergic drug risk

›Thorough medication reconciliation before methylene blue

›Higher risk of serotonin syndrome

›Renal impairment prevalent

›Methylene blue dose adjustment required

›eGFR calculation before dosing

›Phenazopyridine use common for urinary symptoms

›High-risk medication in older adults

›Automatic refills without monitoring

›Disposition bias

›Admission threshold lower in geriatric patients

›Delirium may be presenting symptom masking MetHb diagnosis

›Fall risk and functional decline monitoring

Pediatrics

›Infant-specific vulnerability

›Infants <6 months highest risk

›Lower cytochrome b5 reductase activity than adults

›Fetal HbF more readily oxidized than adult HbA

›Symptomatic at MetHb levels well tolerated by adults

›Blue baby syndrome

›Nitrate-contaminated well water primary cause

›WHO limit 10 mg/L nitrate for infant formula water

›Vegetable purees (spinach, beets, carrots) implicated in infants <4 months

›Pediatric dosing

›Methylene blue weight-based dosing

›1 mg/kg IV over 5-30 minutes (same mg/kg dose as adults)

›Maximum single dose 7 mg/kg to avoid paradoxical effect

›Repeat at 1 hour if inadequate response

›Ascorbic acid adjunct

›25 mg/kg IV for infants and neonates

›G6PD-independent pathway

›Congenital methemoglobinemia management in children

›Type I CYB5R3 deficiency

›Ascorbic acid 0.3 g/day orally for cosmetic cyanosis

›Riboflavin 20 mg/day alternative

›Methylene blue for acute exacerbations

›Type II CYB5R3 deficiency

›Limited treatment benefit for neurological symptoms

›Multidisciplinary neurology and genetics involvement

›Differential diagnosis emphasis

›Cyanotic congenital heart disease priority exclusion

›Echocardiogram in all cyanotic neonates without clear toxic exposure

›Child protection consideration in recurrent unexplained cases

10Background/b79

Epidemiology

›Frequency and burden

›Acquired methemoglobinemia incidence

›Estimated 1 per 100,000 persons per year in general population

›Higher in hospitalized patients undergoing instrumented procedures

›Over two-thirds of clinically significant cases attributed to benzocaine, phenazopyridine, and dapsone

›Occupational and environmental cases

›Aniline dye workers and agricultural workers at elevated risk

›Propanil herbicide historically associated with outbreaks

›Infant and neonatal epidemiology

›Well water contamination predominant source in rural populations

›Seasonal clustering with higher nitrate runoff

›Congenital methemoglobinemia prevalence

›CYB5R3 deficiency: rare, autosomal recessive

›Increased prevalence in genetically isolated populations (Navajo, Alaskan Native)

›Hemoglobin M disease: very rare, autosomal dominant

›Mortality and severity data

›Shock at presentation sole independent predictor of mortality

›MetHb >70% associated with high case fatality rate

›Excellent prognosis with early antidote administration

›10-year retrospective studies demonstrate low overall mortality with prompt treatment

Pathophysiology

›Hemoglobin oxidation mechanism

›Normal hemoglobin state

›Iron in ferrous (Fe2+) state binds oxygen reversibly

›Normal MetHb fraction <3% maintained by reductive pathways

›Oxidation to methemoglobin

›Iron oxidized to ferric (Fe3+) state

›Fe3+ cannot bind oxygen

›Remaining Fe2+ hemes bind oxygen with increased affinity

›Oxygen-hemoglobin dissociation curve shifts left

›Reduced oxygen unloading to tissues — functional anemia

›Direct vs indirect oxidizers

›Direct oxidizers act immediately (nitrites, benzocaine, phenazopyridine)

›Indirect oxidizers require metabolic activation (dapsone via hydroxylamine metabolite, primaquine)

›Endogenous reductive pathways

›Cytochrome b5 reductase (primary pathway)

›NADH-dependent reduction of MetHb

›Accounts for >95% of normal MetHb reduction

›Deficiency causes congenital methemoglobinemia

›NADPH methemoglobin reductase (secondary pathway)

›Normally minor contribution

›Activated by methylene blue — becomes therapeutic pathway

›Requires functional G6PD to generate NADPH via pentose phosphate pathway

›Ascorbic acid and glutathione

›Minor accessory reductive roles

›Therapeutic relevance when primary pathway overwhelmed

›G6PD deficiency impact

›NADPH generation impaired

›Methylene blue cannot activate NADPH reductase pathway

›Oxidative stress causes concurrent hemolytic anemia

›Affects approximately 2% of US population with X-linked inheritance

Therapeutic Considerations

›Methylene blue pharmacology

›MAOI activity mandates serotonin syndrome vigilance

›Serotonergic drug interaction affects clinical treatment decision

›Risk-benefit analysis required when serotonergic drugs are present

›Dose response considerations

›Therapeutic: 1-2 mg/kg reduces MetHb via NADPH pathway

›Paradoxical toxicity: >7 mg/kg causes direct hemoglobin oxidation

›Cumulative dose tracking important in multiple-dose scenarios

›Renal elimination

›Dose reduction in moderate-severe renal impairment

›Dialysis does not significantly clear methylene blue

›Cimetidine adjunct rationale

›CYP2C9 inhibition reduces dapsone hydroxylamine formation

›Specifically applicable to dapsone-induced methemoglobinemia

›May reduce need for repeated methylene blue doses

›Dose 400 mg PO three times daily during active dapsone course

›Alternative antidote evidence base

›Ascorbic acid

›NADH-independent non-enzymatic reduction pathway

›Effective when methylene blue contraindicated

›Response slower — hours to days in chronic cases

›Exchange transfusion evidence

›Case series support in refractory severe cases

›No randomized trial evidence given rarity

›Expert consensus recommendation (ACEP Level C)

›Hyperbaric oxygen

›Increases dissolved O2 up to 6x at 3 ATA

›Bridges to definitive treatment in intractable cases

›Logistical limitations in acute setting

11Patient Discharge Instructions/pdi31

copy discharge instructions

›Methemoglobinemia home care

›Understanding your diagnosis

›Your blood was temporarily unable to carry oxygen due to a chemical that affected your hemoglobin

›The treatment given in the emergency department has corrected this in most cases

›Recovery is typically complete once the cause is removed

›Medication instructions

›Stop using the medication or substance identified as the cause

›Do not restart without speaking to your doctor

›If the cause was a prescription medication, contact the prescribing doctor before stopping any other medications

›Activity and diet

›Light activity for 24-48 hours

›Stay well hydrated

›Avoid alcohol while recovering

›Warning signs to return to the ER immediately

›Bluish or gray color of lips, face, or fingertips

›Trouble breathing or shortness of breath at rest

›Severe dizziness or fainting

›Chest pain or palpitations

›Confusion, severe headache, or inability to stay awake

›Muscle weakness or inability to walk

›Symptoms return after initially improving

›Follow-up instructions

›See your doctor within 2-3 days

›If you take dapsone, you need closer monitoring for the next 24-48 hours as symptoms can return

›If your doctor ordered a G6PD test, ensure results are followed up

›If a family member also has lifelong bluish skin color, mention this to your doctor

›Prevention

12References/r19

Guidelines and key sources

›Primary evidence sources

›Ash-Bernal R, Wise R, Wright SM. Acquired methemoglobinemia: a retrospective series of 138 cases at 2 teaching hospitals. Medicine (Baltimore). 2004

›Wright RO, Lewander WJ, Woolf AD. Methemoglobinemia: etiology, pharmacology, and clinical management. Ann Emerg Med. 1999

›Skold A, Cosco DL, Klein R. Methemoglobinemia: pathogenesis, diagnosis, and management. South Med J. 2011

›US FDA prescribing information for methylene blue (ProvayBlue) including serotonin syndrome boxed warning

›Pharmacology and antidote references

›Methylene blue prescribing information: 1 mg/kg IV; repeat once; renal dose adjustment for eGFR 15-59

›Cimetidine adjunct for dapsone-induced methemoglobinemia: Sica DA et al. clinical evidence

›G6PD deficiency prevalence and methylene blue interaction: WHO Global Report on G6PD Deficiency

›Pediatric and neonatal sources

›American Academy of Pediatrics policy on infant formula water and nitrate contamination

›WHO nitrate limit for drinking water: 10 mg/L for infant safety

›Congenital methemoglobinemia: Percy MJ, Lappin TR. Recessive congenital methaemoglobinaemia: cytochrome b5 reductase deficiency. Br J Haematol. 2008

Society recommendations

›Evidence levels applied in this document

›ACEP Level B recommendation for co-oximetry as definitive diagnostic standard

›ACEP Level C recommendation for exchange transfusion in methylene-blue-refractory cases

›Class I recommendation for methylene blue in symptomatic acquired methemoglobinemia

›Class IIa recommendation for ascorbic acid as alternative or adjunct when methylene blue contraindicated

›Expert consensus: poison control center consultation for all significant cases

Evidence & Review

Evidence & Review